AstraZeneca secures Fusion Pharmaceuticals in $2.4bn deal to advance cancer treatment
AstraZeneca has finalized the acquisition of Fusion Pharmaceuticals Inc., a significant move valued at approximately $2.4 billion, designed to enhance its oncology portfolio by incorporating ... Read More
AstraZeneca to acquire Fusion Pharmaceuticals to boost cancer radioconjugate development
In a strategic move to revolutionize cancer treatment, AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a pioneer in the development of ... Read More